Poultry Pharmaceuticals Market Size is valued at USD 6.72 Bn in 2022 and is predicted to reach USD 14.03 Bn by the year 2031 at an 8.68% CAGR during the forecast period for 2023-2031.
Poultry pharmaceuticals, referred to as poultry medications or veterinary drugs for poultry, encompass a range of pharmaceutical treatments specifically formulated to promote the health and overall welfare of poultry, including chickens, turkeys, ducks, and other domestic fowl. The poultry pharmaceutical sector has a significant impact on the healthcare system worldwide, from patients in need of medication to doctors interested in cutting-edge research. Keeping up with the latest developments in the market is essential if you want to succeed. Poultry pharmaceutical businesses increase the birds' immune systems so that they manufacture antibodies much more quickly to fight off invaders, hence halting the spread of a particular disease. Vaccines for chickens are critical for preventing illness outbreaks. Vaccine development efforts have primarily focused on fighting viral infections in poultry. Vaccines can be administered by the nares, oral cavity, eyes, skin, or musculature.
In addition, the number of medicines that have been licensed for use and the necessity for poultry vaccinations to cure diseases are expected to propel market expansion over the forecast period. A poultry farm's profitability and productivity are directly correlated to the quality of the birds' health care.
However, the use of poultry vaccines has a wide range of consequences: mild discharge from the eyes and nose, local swelling and discomfort at the vaccination site, a loss of appetite and energy, sneezing, a mild temperature, and a minor cough are all symptoms that may occur locally. Thus, this aspect challenges the expansion of the market. The spread of COVID-19 has considerably impacted the demand for poultry healthcare.
Animal items like meat, milk, and eggs had trouble making it to needs in the beginning because of the disruption in the supply chain caused by the international embargo. As the number of reported instances of COVID-19 has decreased, trade and agricultural output have increased, leading to better care and nutrition for the hens, which has raised the need for poultry healthcare, propelling the market forward throughout the projection period. The increasing prevalence of zoonotic infections, together with the increased demand for poultry-derived food products, are all factors that are driving market expansion.
Competitive Landscape
Some Major Key Players In The Poultry Pharmaceuticals Market:
- Aervoe Industries Inc.
- Bayer AG,
- Bimeda
- Ceva Sante Animale
- Elanco Animal Health (Eli Lilly and Company)
- Merck Animal Health
- Merial Animal Health (Sanofi)
- Virbac
- Boehringer Ingelheim
- Zoetis, Inc.
- Pacific GeneTech
- Avivagen Inc.
- Hester Biosciences Limited
- Venkys India
- Calier
- KM Biologics
- Others
Market Segmentation:
The poultry pharmaceutical market is segmented based on product type, feed additives and animal type. As per the product type, the market is segmented into drugs, verotoxin, other drug products, vaccines, INNOVAX, NOBILIS, poulvac, and other vaccine products. By feed additives the market is segmented into VIGOSINE, Amnovit, and other feed additives. By animal type, the market is segmented into chicken, turkey, duck, goose, and others.
Based On The Product Type, The Drug Segment Of The Poultry Pharmaceuticals Market Is Accounted As A Major Contributor To The Poultry Pharmaceuticals Market
The drugs category is expected to hold a major global market share in 2022. The rising incidence of Zoonotic diseases is driving growth in the drug segment of the poultry pharmaceuticals market over the forecast period. To protect the health and wellbeing of the birds, to prevent the emergence of antibiotic resistance, and to address other potential problems, it is crucial for poultry farmers and veterinarians to administer these medications sensibly and in line with the law.
Chicken Segment To Witness Growth At A Rapid Rate
Chicken is projected to grow rapidly in the global poultry pharmaceuticals market. Due to this, chicken is predicted to be the most lucrative sub-segment of the global poultry pharmaceuticals market over the forecast period. Growth in this sector is anticipated during the projection period to be driven by the increased government measures to preventative vaccines in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Poultry Pharmaceuticals Market Holds A Significant Revenue Share
The North American poultry pharmaceuticals Market is expected to record the maximum market share in revenue in the near future. It can be attributed to increased demand in the global poultry pharmaceuticals market, which may be traced back to the rising incidence of Zoonotic and infectious diseases. In addition, Asia Pacific is estimated to grow rapidly because more people are learning about the importance of preventing diseases like polio and rabies. The government is providing free inoculation camps to protect more people from contagious diseases.
Recent Developments:
- In April 2022, Ceva Santé Animale has recently disclosed the establishment of a collaborative enterprise in Japan with Mitsui. The primary objective of the newly established joint venture was to enhance Ceva's corporate reputation and business strategy with prospective Japanese partners. This facilitated Ceva's substantial expansion in Japan at an expedited pace.
- In Aug 2022, Bimeda, an animal health distributor, has just acquired Afrivet, a veterinary pharmaceutical firm. This acquisition has resulted in Bimeda currently possessing the most extensive presence among all animal health companies operating in Africa.
Poultry Pharmaceuticals Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 6.72 Bn |
|
Revenue Forecast In 2031 |
USD 14.03 Bn |
|
Growth Rate CAGR |
CAGR of 8.68% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, Animal Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aervoe Industries Inc., Bayer AG, Bimeda, Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, Avivagen Inc., Hester Biosciences Limited, Venkys India, Calier, KM Biologics, Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
